On Oct.25, 2011, Tianjin Ringpu Bio-technology Co., Ltd. (300119.SZ) published its Q1-Q3 Report disclosing that in Jan.-Sep., 2011, it gained operating revenue of RMB 430 million, up 78.3% YoY, and net income of RMB 85 million, up 37.0% YoY. The rapid growth of its performance was mainly driven by the merger with Hubei Longxiang Pharmaceutical Co., Ltd. and its new marketing strategy.

In 2010, after the merger, Ringpu Biology strengthened the supply of APIs and enhanced the competitiveness of veterinary preparations. In Q1-Q3 2011, its veterinary preparations attainted sales revenue of RMB 89.76 million, up 46.3% YoY and became the fastest growing business in Ringpu Biology. Besides, the adoption of a matrix marketing management model also elevated its sales capability significantly. In Q1-Q3 2011, its veterinary biological products reached sales of RMB 230 million, up 27.7% YoY, while veterinary APIs achieved sales of RMB 110 million, accounting for about 26% of the operating revenue.

As planned, Ringpu Biology will endeavor to seek for cooperation or merger opportunities in the veterinary drug field so as to improve its production lines constantly.

Operating Revenue of Tianjin Ringpu Bio-technology (by Product), 2011-2013E (RMB mln)